175 related articles for article (PubMed ID: 38494543)
21. Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
Minnema MC; Yin X; Davi R; Keeping S; Park JE; Itani T; Hadjivassileva T; Castaigne JG; Damico Khalid R; Zhou L; Wu JJ; Shah BD
Leuk Lymphoma; 2024 May; ():1-10. PubMed ID: 38785408
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.
Marchetti M; Visco C
Leuk Lymphoma; 2023; 64(8):1442-1450. PubMed ID: 37229538
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Chong EA; Chong ER; Therwhanger D; Nasta SD; Landsburg DJ; Barta SK; Svoboda J; Gerson JN; Ghilardi G; Paruzzo L; Fraietta JA; Weber E; Stefano N; Porter DL; Frey NV; Garfall AL; Ruella M; Schuster SJ
Transplant Cell Ther; 2024 Mar; ():. PubMed ID: 38494076
[TBL] [Abstract][Full Text] [Related]
24. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
Munoz JL; Wang Y; Jain P; Wang M
Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
[TBL] [Abstract][Full Text] [Related]
25. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Rejeski K; Wang Y; Albanyan O; Munoz J; Sesques P; Iacoboni G; Lopez-Corral L; Ries I; Bücklein VL; Mohty R; Dreyling M; Baluch A; Shah B; Locke FL; Hess G; Barba P; Bachy E; Lin Y; Subklewe M; Jain MD
Am J Hematol; 2023 Nov; 98(11):1699-1710. PubMed ID: 37584447
[TBL] [Abstract][Full Text] [Related]
26. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
28. [New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
Rousseau A; Thieblemont C
Bull Cancer; 2021 Feb; 108(2):142-144. PubMed ID: 33531153
[No Abstract] [Full Text] [Related]
29. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
30. FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
Telaraja D; Kasamon YL; Collazo JS; Leong R; Wang K; Li P; Dahmane E; Yang Y; Earp J; Grimstein M; Rodriguez LR; Theoret MR; Gormley NJ
Clin Cancer Res; 2024 Jan; 30(1):17-22. PubMed ID: 37624619
[TBL] [Abstract][Full Text] [Related]
31. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Dong J; Adhikary S; Zhou L; Schuberth PC; Faghmous I; Masouleh BK; Houot R
J Hematol Oncol; 2022 Dec; 15(1):170. PubMed ID: 36494725
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B
J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729
[TBL] [Abstract][Full Text] [Related]
33. CAR T-Cell therapy for the management of mantle cell lymphoma.
Huang Z; Chavda VP; Bezbaruah R; Dhamne H; Yang DH; Zhao HB
Mol Cancer; 2023 Mar; 22(1):67. PubMed ID: 37004047
[TBL] [Abstract][Full Text] [Related]
34. Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
McCulloch R
Br J Haematol; 2023 Aug; 202(4):718-719. PubMed ID: 37188352
[TBL] [Abstract][Full Text] [Related]
35. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
Thompson PA; Tam CS
Blood; 2023 Jun; 141(26):3137-3142. PubMed ID: 37156004
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
Lionel AC; Gurumurthi A; Fetooh A; Eldaya R; Ahmed S; Iyer SP; Nastoupil LJ; Westin J; Nair R; Fayad L; Malpica L; Tummala S; Flowers C; Neelapu SS; Wang ML; Jain P
Leuk Lymphoma; 2024 May; 65(5):669-673. PubMed ID: 38248629
[No Abstract] [Full Text] [Related]
37. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma.
Mohty R; Kharfan-Dabaja MA
Ther Adv Hematol; 2022; 13():20406207221142133. PubMed ID: 36544864
[TBL] [Abstract][Full Text] [Related]
38. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
39. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Bond DA; Maddocks KJ
Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
[TBL] [Abstract][Full Text] [Related]
40. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Wang M; Siddiqi T; Gordon LI; Kamdar M; Lunning M; Hirayama AV; Abramson JS; Arnason J; Ghosh N; Mehta A; Andreadis C; Solomon SR; Kostic A; Dehner C; Espinola R; Peng L; Ogasawara K; Chattin A; Eliason L; Palomba ML
J Clin Oncol; 2024 Apr; 42(10):1146-1157. PubMed ID: 38072625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]